Recent Quotes (30 days)

You have no recent quotes
chg | %

Merus Labs International Inc  

(Public, TSE:MSL)   Watch this stock  
Find more results for MSL
-0.01 (-0.57%)
Jul 25 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.70 - 1.76
52 week 1.47 - 3.46
Open 1.76
Vol / Avg. 144,255.00/367,164.00
Mkt cap 178.52M
P/E     -
Div/yield     -
EPS -0.06
Shares 102.60M
Beta 1.02
Inst. own     -
Oct 19, 2016
Q3 2016 Merus Labs International Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 8, 2016
Merus Labs International Inc at Jefferies Healthcare Conference
May 12, 2016
Q2 2016 Merus Labs International Inc Earnings Call
May 11, 2016
Q2 2016 Merus Labs International Inc Earnings Release

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -17.39% -0.49%
Operating margin -5.85% 12.66%
EBITD margin - 61.48%
Return on average assets -4.25% -0.10%
Return on average equity -7.15% -0.17%
Employees 6 -
CDP Score - -


100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151
+1-416-5933701 (Phone)
+1-416-5934434 (Fax)

Website links


Merus Labs International Inc. (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women's health and anti-infectives. Its products include Factive, Emselex/Enable and Vancocin. Enablex (darifenacin) or Emselex is used in treatment of urinary urgency and incontinence. Vancocin is used in treatment of C. difficile infection (CDI). Factive (Gemifloxacin Mesylate tablets) is the only Food and Drug Administration approved quinolone with five day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia.

Officers and directors

Michael S. Cloutier Independent Chairman of the Board
Barry Fishman Chief Executive Officer, Director
Michael Bumby Chief Financial Officer
Age: 51
Robert McLay Vice President - Sales and Marketing
Frank Rotmann Vice President and Head of European Operations
Robert Bloch M.D. Director
Theresa Sheila Firestone Independent Director
David D. Guebert CPA Independent Director
Robert S. Pollock Independent Director
Timothy G. Sorensen Independent Director